National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 1514469

Government Disclaimer on use of this data

History of Changes from the VAERS Wayback Machine

First Appeared on 7/30/2021

VAERS ID: 1514469
VAERS Form:2
Age:
Sex:Male
Location:Ohio
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted:0000-00-00
Entered:2021-07-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH - / 2 - / -

Administered by: Unknown      Purchased by: ??
Symptoms: Body temperature, Catheterisation cardiac, Computerised tomogram, Echocardiogram, Electrocardiogram, Heart rate, Myocarditis, Oxygen saturation, Respiratory rate, Ultrasound scan, Ejection fraction, Computerised tomogram coronary artery, Troponin, Investigation, Blood pressure measurement, Magnetic resonance imaging heart, SARS-CoV-2 test

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? Yes
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: SARS-CoV-2 infection (approximately two months prior to the onset of his symptoms); Tobacco user
Allergies:
Diagnostic Lab Data: Test Name: blood pressure; Result Unstructured Data: Test Result:121/54 mmHg; Test Name: Body temperature; Result Unstructured Data: Test Result:98.4 Fahrenheit; Comments: orally; Test Name: heart catherization; Result Unstructured Data: Test Result:whichwas unremarkable.; Test Name: Cardiac computed tomography; Result Unstructured Data: Test Result:showed a coronary artery calciumscore of zero and; Comments: showed a coronary artery calcium score of zero and no pathology.; Test Name: coronary artery calcium score; Result Unstructured Data: Test Result:zero; Test Name: Inpatient echocardiogram; Result Unstructured Data: Test Result:showed left ventricular ejection fraction (LVEF) 5; Comments: showed left ventricular ejection fraction (LVEF) 59% with no other abnormalities; Test Name: left ventricular ejection fraction; Test Result: 59 %; Test Name: electrocardiogram; Result Unstructured Data: Test Result:ST segment elevation; Comments: diffuse concave ST segment elevations; Test Name: heart rate; Result Unstructured Data: Test Result:113; Comments: beats per minute; Test Name: examination; Result Unstructured Data: Test Result:pain worsened with sitting and improved while lyin; Comments: pain worsened with sitting and improved while lying flat.; Test Name: Cardiac magnetic resonance imaging; Result Unstructured Data: Test Result:positive for myocarditis; Test Name: SpO2; Test Result: 100 %; Comments: on room air.; Test Name: respirations; Result Unstructured Data: Test Result:20; Comments: breaths per minute; Test Name: PCR/SARS CoV-2; Test Result: Negative ; Test Name: SARS-CoV-2; Test Result: Positive ; Test Name: troponin; Result Unstructured Data: Test Result:89 ng/ml; Comments: which increased on repeat examination; Test Name: troponin; Result Unstructured Data: Test Result:108 ng/ml; Comments: increased to a maximum; Test Name: ultrasound; Result Unstructured Data: Test Result:revealed a small pericardial effusion without evid; Comments: revealed a small pericardial effusion without evidence of tamponade, which supported the diagnosis.
CDC 'Split Type': USPFIZER INC202100910810

Write-up: Myocarditis; This is a literature report. A 20-year old male with no prior medical history presented to the emergency department (ED) with a chief complaint of midsternal chest pain that radiated to the left side. The pain started in the morning and remained while resting. The patient also complained of mild shortness of breath secondary to pain. Upon examination, pain worsened with sitting and improved while lying flat. The patient had received his second dose of the Pfizer-BioNTech (BNT 162b2) vaccination two days prior to the onset of chest pain. The patient denied history of venous thromboembolism or family history of cardiovascular disease. The patient had a history of tobacco use. Approximately two months prior to ED presentation, the patient tested positive for SARS-CoV-2 and recovered with no sequalae. In the ED his initial troponin was 89 ng/L and increased to a maximum of 108 ng/L. The patient tested negative for SARS CoV-2 by PCR. Vital signs revealed blood pressure 121/54 mm/Hg, heart rate 113 beats per minute, temperature 98.4 degree F orally, respirations 20 breaths per minute, SpO2 100% on room air. The patient''s electrocardiogram showed diffuse concave ST segment elevations with PR depressions. (Fig. 1, Note the somewhat diffuse concave ST elevations with PR depressions (V5-V6, II, aVF).). Myocarditis was suspected and bedside ultrasound revealed a small pericardial effusion without evidence of tamponade, which supported the diagnosis. The patient was subsequently given a dose of colchicine 0.6 mg and then admitted to the hospital for further evaluation. Inpatient echocardiogram showed left ventricular ejection fraction (LVEF) 59% with no other abnormalities. The patient underwent left heart catherization which was unremarkable. Cardiac computed tomography showed a coronary artery calcium score of zero and no pathology. Cardiac magnetic resonance imaging was positive for myocarditis. After his chest pain resolved, the patient was discharged with colchicine 0.6 mg for three months, metoprolol XL 12.5 mg daily for three months, and ibuprofen 600 mg three times daily for two weeks. Myocarditis is most often caused by a viral infection; however, other causes include idiopathic, autoimmune, and hypersensitivity. When there is an infectious etiology, patients typically present with flu-like symptoms in addition to chest pain. Myocarditis has also been reported following live viral vaccinations, most notably the smallpox vaccine. From the early 1950s until 2003, six cases of cardiac complications following smallpox vaccination were reported. A campaign to vaccinate personnel against smallpox with the Dry Vax vaccine between 2002 and 2003 resulted in 67 cases of myocarditis or pericarditis out of the 540,824 personnel vaccinated. Due to concern for cardiac complications following smallpox vaccination, a study was conducted to evaluate risk of myocarditis and pericarditis in live viral vaccinations. Of the 416,629 vaccinated adults studied, only one case of pericarditis and zero cases of myocarditis were identified following vaccination. The authors concluded there was no increased risk of myopericarditis following live viral vaccination. While this case demonstrates a clear temporal association of vaccine-related myocarditis and other potential causes of myo-carditis are unlikely, a true cause-and-effect relationship could not be established nor determined. The author hope this case provides emergency medicine physicians additional information on evaluating potential post COVID-19 vaccination myocarditis. Information about lot/batch number cannot be obtained.; Sender''s Comments: Based on the current available information and a possible contributory role of the suspect product BNT162B2 to the development of event myocarditis cannot be totally excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to RAs, Ethics Committees, and Investigators, as appropriate.

New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1514469&WAYBACKHISTORY=ON


Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166